Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 29.04% is 58% above its 5-year average of 18.32%, near the high end of its 5-year range (-62.37%–39.28%).
As of the fiscal period ended Tuesday, March 31, 2026. 1.33% above its 12-month average of 28.65%.
Reported quarterly profit margin; no daily interpolation.
NET PROFIT MARGIN
29.04%
NET PROFIT MARGIN AVG TTM
28.65%
NET PROFIT MARGIN AVG 3Y
24.12%
NET PROFIT MARGIN AVG 5Y
22.36%
NET PROFIT MARGIN AVG 10Y
27.61%
NET PROFIT MARGIN AVG 15Y
31.36%
NET PROFIT MARGIN AVG 20Y
32.83%
CURRENT VS TTM AVG
+1.33%
CURRENT VS 3Y AVG
+20.41%
CURRENT VS 5Y AVG
+29.87%
CURRENT VS 10Y AVG
+5.16%
CURRENT VS 15Y AVG
-7.40%
CURRENT VS 20Y AVG
-11.54%
SECTOR MEDIAN · HEALTHCARE
9.05%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+220.85%
vs the sector median at left
Gilead Sciences, Inc.
Market Cap
$161.66B
Net Profit Margin
29.04%
TTM Avg
28.65%
3Y Avg
24.12%
5Y Avg
22.36%
Market Cap
$182.90B
Net Profit Margin
11.65%
TTM Avg
23.34%
3Y Avg
19.20%
5Y Avg
17.71%
Market Cap
$137.13B
Net Profit Margin
15.95%
TTM Avg
15.52%
3Y Avg
19.51%
5Y Avg
19.37%
Market Cap
$133.41B
Net Profit Margin
18.87%
TTM Avg
-1.95%
3Y Avg
6.91%
5Y Avg
3.59%
Market Cap
$133.25B
Net Profit Margin
0.72%
TTM Avg
0.84%
3Y Avg
1.34%
5Y Avg
1.79%
Market Cap
$131.47B
Net Profit Margin
17.19%
TTM Avg
15.23%
3Y Avg
12.72%
5Y Avg
10.53%
Market Cap
$124.86B
Net Profit Margin
14.43%
TTM Avg
13.09%
3Y Avg
13.60%
5Y Avg
12.87%
Market Cap
$124.82B
Net Profit Margin
28.45%
TTM Avg
28.09%
3Y Avg
25.67%
5Y Avg
26.14%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $161.66B | 29.04% | 28.65% | 24.12% | 22.36% |
| Pfizer Inc. (PFE)vs › | $142.54B | 11.83% | 12.51% | 14.97% | 18.18% |
| Abbott Laboratories (ABT)vs › | $182.90B | 11.65% | 23.34% | 19.20% | 17.71% |
| Danaher Corporation (DHR)vs › | $137.13B | 15.95% | 15.52% | 19.51% | 19.37% |
| Bristol-Myers Squibb Company (BMY)vs › | $133.41B | 18.87% | -1.95% | 6.91% | 3.59% |
| CVS Health Corp. (CVS)vs › | $133.25B | 0.72% | 0.84% | 1.34% | 1.79% |
| AstraZeneca PLC (AZN)vs › | $131.47B | 17.19% | 15.23% | 12.72% | 10.53% |
| Stryker Corporation (SYK)vs › | $124.86B | 14.43% | 13.09% | 13.60% | 12.87% |
| Intuitive Surgical, Inc. (ISRG)vs › | $124.82B | 28.45% | 28.09% | 25.67% | 26.14% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $121.09B | 35.40% | 13.94% | 25.44% | 29.40% |
Operating Margin
38.3%
Net Profit Margin
29.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 29.04% |
| 2025-12-31 | 27.55% |
| 2025-09-30 | 39.28% |
| 2025-06-30 | 27.68% |
| 2025-03-31 | 19.72% |
| 2024-12-31 | 23.56% |
| 2024-09-30 | 16.61% |
| 2024-06-30 | 23.21% |
| 2024-03-31 | -62.37% |
| 2023-12-31 | 20.09% |
| 2023-09-30 | 30.92% |
| 2023-06-30 | 15.84% |
| 2023-03-31 | 15.90% |
| 2022-12-31 | 22.20% |
| 2022-09-30 | 25.40% |
| 2022-06-30 | 18.27% |
| 2022-03-31 | 0.29% |
| 2021-12-31 | 5.27% |
| 2021-09-30 | 34.93% |
| 2021-06-30 | 24.48% |
| 2021-03-31 | 26.92% |
| 2020-12-31 | 20.90% |
| 2020-09-30 | 5.47% |
| 2020-06-30 | -64.92% |
| 2020-03-31 | 27.96% |
| 2019-12-31 | 45.86% |
| 2019-09-30 | -20.79% |
| 2019-06-30 | 33.07% |
| 2019-03-31 | 37.40% |
| 2018-12-31 | 0.05% |
| 2018-09-30 | 37.47% |
| 2018-06-30 | 32.17% |
| 2018-03-31 | 30.23% |
| 2017-12-31 | -64.97% |
| 2017-09-30 | 41.74% |
| 2017-06-30 | 43.03% |
| 2017-03-31 | 41.54% |
| 2016-12-31 | 42.46% |
| 2016-09-30 | 44.40% |
| 2016-06-30 | 44.97% |
| 2016-03-31 | 45.75% |
| 2015-12-31 | 55.06% |
| 2015-09-30 | 55.46% |
| 2015-06-30 | 54.49% |
| 2015-03-31 | 57.06% |
| 2014-12-31 | 47.67% |
| 2014-09-30 | 45.20% |
| 2014-06-30 | 55.94% |
| 2014-03-31 | 44.55% |
| 2013-12-31 | 25.37% |
| 2013-09-30 | 28.34% |
| 2013-06-30 | 27.92% |
| 2013-03-31 | 28.53% |
| 2012-12-31 | 29.46% |
| 2012-09-30 | 27.84% |
| 2012-06-30 | 29.58% |
| 2012-03-31 | 19.36% |
| 2011-12-31 | 30.23% |
| 2011-09-30 | 34.93% |
| 2011-06-30 | 34.92% |
| 2011-03-31 | 33.81% |
| 2010-12-31 | 31.49% |
| 2010-09-30 | 36.38% |
| 2010-06-30 | 36.95% |
| 2010-03-31 | 40.99% |
| 2009-12-31 | 39.47% |
| 2009-09-30 | 37.36% |
| 2009-06-30 | 34.69% |
| 2009-03-31 | 38.49% |
| 2008-12-31 | 39.78% |
| 2008-09-30 | 36.75% |
| 2008-06-30 | 34.02% |
| 2008-03-31 | 38.81% |
| 2007-12-31 | 36.69% |
| 2007-09-30 | 37.62% |
| 2007-06-30 | 38.92% |
| 2007-03-31 | 39.61% |
| 2006-12-31 | -185.23% |
| 2006-09-30 | -6.97% |
| 2006-06-30 | 38.69% |
| 2006-03-31 | 37.91% |
| 2005-12-31 | 46.22% |
| 2005-09-30 | 36.32% |
| 2005-06-30 | 39.57% |
| 2005-03-31 | 36.50% |
| 2004-12-31 | 29.83% |
| 2004-09-30 | 34.72% |
| 2004-06-30 | 34.86% |
| 2004-03-31 | 37.02% |
| 2003-12-31 | 73.08% |
| 2003-09-30 | 36.48% |
| 2003-06-30 | 42.02% |
| 2003-03-31 | -265.32% |
| 2002-12-31 | 24.46% |
| 2002-09-30 | 15.49% |
| 2002-06-30 | 18.02% |
